- Home
- REVG vs ITRM Comparison
REVG vs ITRM Comparison
Compare REVG & ITRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REVG
- ITRM
- Stock Information
- Founded
- REVG 2008
- ITRM 2015
- Country
- REVG United States
- ITRM Ireland
- Employees
- REVG N/A
- ITRM N/A
- Industry
- REVG Auto Manufacturing
- ITRM Biotechnology: Pharmaceutical Preparations
- Sector
- REVG Consumer Discretionary
- ITRM Health Care
- Exchange
- REVG Nasdaq
- ITRM Nasdaq
- Market Cap
- REVG N/A
- ITRM 37.7M
- IPO Year
- REVG 2017
- ITRM 2018
- Fundamental
- Price
- REVG $29.82
- ITRM $1.08
- Analyst Decision
- REVG Hold
- ITRM Strong Buy
- Analyst Count
- REVG 4
- ITRM 1
- Target Price
- REVG $33.75
- ITRM $5.00
- AVG Volume (30 Days)
- REVG 921.2K
- ITRM 300.3K
- Earning Date
- REVG 06-04-2025
- ITRM 05-12-2025
- Dividend Yield
- REVG 0.81%
- ITRM N/A
- EPS Growth
- REVG N/A
- ITRM N/A
- EPS
- REVG 1.77
- ITRM N/A
- Revenue
- REVG $2,319,300,000.00
- ITRM N/A
- Revenue This Year
- REVG $2.51
- ITRM N/A
- Revenue Next Year
- REVG $6.97
- ITRM $150.10
- P/E Ratio
- REVG $16.88
- ITRM N/A
- Revenue Growth
- REVG N/A
- ITRM N/A
- 52 Week Low
- REVG $20.51
- ITRM $0.81
- 52 Week High
- REVG $36.00
- ITRM $3.02
- Technical
- Relative Strength Index (RSI)
- REVG 43.78
- ITRM 32.84
- Support Level
- REVG $28.76
- ITRM $1.05
- Resistance Level
- REVG $32.55
- ITRM $1.16
- Average True Range (ATR)
- REVG 1.83
- ITRM 0.08
- MACD
- REVG -0.08
- ITRM -0.00
- Stochastic Oscillator
- REVG 44.71
- ITRM 13.04
About ITRM Iterum Therapeutics plc
Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.